Abstract
Variants in 11 genes of the RAS/MAPK signaling pathway have been causally linked to the neuro-cardio-facio-cutaneous syndromes group (NCFCS). Recently, A2ML1 and RIT1 were also associated with these syndromes. Because of the genetic and clinical heterogeneity of NCFCS, it is challenging to define strategies for their molecular diagnosis. The aim of this study was to develop and validate a massive parallel sequencing (MPS)-based strategy for the molecular diagnosis of NCFCS. A multiplex PCR-based strategy for the enrichment of the 13 genes and a variant prioritization pipeline was established. Two sets of genomic DNA samples were studied using the Ion PGM System: (1) training set (n=15) to optimize the strategy and (2) validation set (n=20) to validate and evaluate the power of the new methodology. Sanger sequencing was performed to confirm all variants and low covered regions. All variants identified by Sanger sequencing were detected with our MPS approach. The methodology resulted in an experimental approach with a specificity of 99.0% and a maximum analytical sensitivity of ≥98.2% with a confidence of 99%. Importantly, two patients (out of 20) harbored described disease-causing variants in genes that are not routinely tested (RIT1 and SHOC2). The addition of less frequently altered genes increased in ≈10% the diagnostic yield of the strategy currently used. The presented workflow provides a comprehensive genetic screening strategy for patients with NCFCS in a fast and cost-efficient manner. This approach demonstrates the potential of a combined MPS–Sanger sequencing-based strategy as an effective diagnostic tool for heterogeneous diseases.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Tartaglia M, Gelb BD : Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci 2010; 1214: 99–121.
Nora JJ, Nora AH, Sinha AK, Spangler RD, Lubs HA : The Ullrich-Noonan syndrome (Turner phenotype). Am J Dis Child 1974; 127: 48–55.
Tidyman WE, Rauen KA : Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med 2008; 10: e37.
Baldassarre G, Mussa A, Dotta A et al: Prenatal features of Noonan syndrome: prevalence and prognostic value. Prenat Diagn 2011; 31: 949–954.
Digilio MC, Lepri F, Baban A et al: RASopathies: clinical diagnosis in the first year of life. Mol Syndromol 2011; 1: 282–289.
Rodriguez-Viciana P, Tetsu O, Tidyman WE et al: Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006; 311: 1287–1290.
Romano AA, Allanson JE, Dahlgren J et al: Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 2010; 126: 746–759.
Gripp KW, Lin AE : Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations. Genet Med 2012; 14: 285–292.
Martínez-Quintana E, Rodríguez-González F : LEOPARD syndrome: clinical features and gene mutations. Mol Syndromol 2012; 3: 145–157.
Nava C, Hanna N, Michot C et al: Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet 2007; 44: 763–771.
Roberts AE, Allanson JE, Tartaglia M, Gelb BD : Noonan syndrome. Lancet 2013; 381: 333–342.
Aoki Y, Niihori T, Banjo T et al: Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet 2013; 93: 173–180.
Yntema H, Nillesen W, Overman J et alThe identification of a novel gene identified by exome sequencing reveals the upstream components of the RAS/MAPK signaling pathway involved in Noonan syndrome (Abstract/Program #215). Presented at 62nd Annual Meeting of the American Society of Human Genetics, 6–10 November 2012 in San Francisco, California.
Schulz AL, Albrecht B, Arici C et al: Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome. Clin Genet 2008; 73: 62–70.
Nyström AM, Ekvall S, Berglund E et al: Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders. J Med Genet 2008; 45: 500–506.
Program CLA: Molecular Pathology Checklist http://www.cap.org/apps/docs/laboratory_accreditation/checklists/new/molecular_pathology_checklist.pdf.
Gargis AS, Kalman L, Berry MW et al: Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol 2012; 30: 1033–1036.
Rehm HL, Bale SJ, Bayrak-Toydemir P et al: ACMG clinical laboratory standards for next-generation sequencing. Genet Med 2013; 15: 733–747.
Rozen S, Skaletsky H : Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132: 365–386.
Costa JL, Sousa S, Justino A et al: Nonoptical massive parallel DNA sequencing of BRCA1 and BRCA2 genes in a diagnostic setting. Hum Mutat 2013; 34: 629–635.
Quail MA, Smith M, Coupland P et al: A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 2012; 13: 341.
Mattocks CJ, Morris MA, Matthijs G et al: A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet 2010; 18: 1276–1288.
Adzhubei IA, Schmidt S, Peshkin L et al: A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248–249.
Schwarz JM, Rödelsperger C, Schuelke M, Seelow D : MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010; 7: 575–576.
Calabrese R, Capriotti E, Fariselli P, Martelli PL, Casadio R : Functional annotations improve the predictive score of human disease-related mutations in proteins. Hum Mutat 2009; 30: 1237–1244.
Desmet FO, Hamroun D, Lalande M, Collod-Béroud G, Claustres M, Béroud C : Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 2009; 37: e67.
den Dunnen JT, Antonarakis SE : Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000; 15: 7–12.
Wildeman M, van Ophuizen E, den Dunnen JT, Taschner PE : Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker. Hum Mutat 2008; 29: 6–13.
Dames S, Durtschi J, Geiersbach K, Stephens J, Voelkerding KV : Comparison of the Illumina Genome Analyzer and Roche 454 GS FLX for resequencing of hypertrophic cardiomyopathy-associated genes. J Biomol Tech 2010; 21: 73–80.
Jia P, Li F, Xia J et al: Consensus rules in variant detection from next-generation sequencing data. PLoS One 2012; 7: e38470.
Chan M, Ji SM, Yeo ZX et al: Development of a next-generation sequencing method for BRCA mutation screening: a comparison between a high-throughput and a benchtop platform. J Mol Diagn 2012; 14: 602–612.
Brasil AS, Malaquias AC, Wanderley LT et al: Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: does this predict a more severe phenotype? Arq Bras Endocrinol Metabol 2010; 54: 717–722.
Ekvall S, Hagenas L, Allanson J, Anneren G, Bondeson ML : Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype. Am J Med Genet A 2011; 155A: 1217–1224.
Richards CS, Bale S, Bellissimo DB et al: ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med 2008; 10: 294–300.
Tartaglia M, Kalidas K, Shaw A et al: PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002; 70: 1555–1563.
Ferrario VF, Sforza C, Ciusa V, Dellavia C, Tartaglia GM : The effect of sex and age on facial asymmetry in healthy subjects: a cross-sectional study from adolescence to mid-adulthood. J Oral Maxillofac Surg 2001; 59: 382–388.
Digilio MC, Conti E, Sarkozy A et al: Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 2002; 71: 389–394.
Pandit B, Sarkozy A, Pennacchio LA et al: Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007; 39: 1007–1012.
Cordeddu V, Di Schiavi E, Pennacchio LA et al: Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet 2009; 41: 1022–1026.
Ferrero GB, Picco G, Baldassarre G et al: Transcriptional hallmarks of Noonan syndrome and Noonan-like syndrome with loose anagen hair. Hum Mutat 2012; 33: 703–709.
Acknowledgements
This work was funded by Research Grant from Fundação para a Ciência e Tecnologia (ERA-PTG/0001/2010 to AJ; PTDC/BIM-MEC/0650/2012 to JLC) and PPS5 Consórcio DoIT (ADI–Agência de Inovação to JLC). IPATIMUP is an Associate Laboratory of the Portuguese Ministry of Education and Science and is partially supported by FCT, the Portuguese Foundation for Science and Technology.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on European Journal of Human Genetics website
Rights and permissions
About this article
Cite this article
Justino, A., Dias, P., João Pina, M. et al. Comprehensive massive parallel DNA sequencing strategy for the genetic diagnosis of the neuro-cardio-facio-cutaneous syndromes. Eur J Hum Genet 23, 347–353 (2015). https://doi.org/10.1038/ejhg.2014.97
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2014.97
This article is cited by
-
A novel heterozygous RIT1 mutation in a patient with Noonan syndrome, leukopenia, and transient myeloproliferation—a review of the literature
European Journal of Pediatrics (2016)
-
Targeted high-throughput sequencing for genetic diagnostics of hemophagocytic lymphohistiocytosis
Genome Medicine (2015)
